gammaCore to treat asthma in coronavirus infected patients. The U.S. Food and Drug Administration (FDA) authorized the use of gammaCore for the treatment of asthma exacerbations in known or suspected COVID-19 patients. The shares of gammaCore gained over 100% value upon the emergency use authorization (EUA) news, which was announced yesterday.gammaCore was shown to improve asthma. The non-invasive vagus nerve stimulation (nVNS) device, gammaCore, showed relief in patients who are experiencing asthma-related breathing difficulty in prior pilot studies. The EUA was granted based on data from two prospective studies, that showed 73%-93% improvement (in various measures including ability to expel air from lungs and shortness of breath) in patients using gammaCore. The company is yet to provide detailed information on pricing and distribution of gammaCore under the EUA.Compelling stock valuation. We think the FDA’s emergency approval of gammaCore for the treatment of coronavirus patients with asthma exacerbations is a major milestone for the company. We are maintaining our current estimates until further information. We believe the shares are poised to gain value upon this expanded market opportunity. We are reiterating our Outperform rating and $4 price target.Read More >>